A Phase II trial of durvalumab (Medi 4736) in advanced endometrial cancer. A multi-centre Phase II trial to determine the activity and safety of durvalumab in advanced endometrial cancer

Trial Profile

A Phase II trial of durvalumab (Medi 4736) in advanced endometrial cancer. A multi-centre Phase II trial to determine the activity and safety of durvalumab in advanced endometrial cancer

Not yet recruiting
Phase of Trial: Phase II

Latest Information Update: 06 Jun 2017

At a glance

  • Drugs Durvalumab (Primary)
  • Indications Adenocarcinoma; Endometrial cancer
  • Focus Therapeutic Use
  • Acronyms PHAEDRA
  • Most Recent Events

    • 06 Jun 2017 Trial design presented at the 53rd Annual Meeting of the American Society of Clinical Oncology
    • 20 Jan 2017 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top